Premium
Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction
Author(s) -
Constans Joël,
Blann Andrew D.,
Resplandy François,
Parrot Françoise,
Renard Martine,
Seigneur Martine,
Guérin Viviane,
Boisseau Michel,
Conri Claude
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01780.x
Subject(s) - von willebrand factor , thrombomodulin , homocysteine , medicine , folic acid , hyperhomocysteinemia , endothelial dysfunction , vitamin , endocrinology , methionine , risk factor , folic acid supplementation , gastroenterology , biochemistry , biology , platelet , amino acid , thrombin
Hyperhomocysteinaemia is a risk factor for premature atherosclerosis and venous thromboembolic disease. Supplementation with folic acid and vitamin B6 has been shown to decrease plasma homocysteine but data fail to assess an effect on the progression of vascular disease. We measured plasma homocysteine and two markers of endothelial injury (plasma soluble thrombomodulin and von Willebrand factor) at baseline and after 3 months of treatment with folic acid and vitamin B6. After this treatment there was a significant decrease in fasting soluble thrombomodulin (−15 ng/ml, 95%CI 5–22.2). Von Willebrand factor was significantly raised after methionine load at baseline but did not significantly rise after supplementation.